
Loading, please wait...

Loading, please wait...

People living with HIV (PLWH) face a significantly higher risk for allograft rejection after receiving a kidney transplant. While this risk is well-documented, the underlying biological mechanisms remain somewhat elusive. Some researchers have suggested that immune dysregulation and chronic inflammation, driven by HIV latency, might play a role. A new study by Sulaiman A et al. recently explored the connection between the HIV reservoir transplant rejection risk and clinical outcomes in these patients.
In this investigation, the research team focused on kidney transplant recipients who received organs from both HIV-positive and HIV-negative donors. They specifically looked at the latent viral reservoir (LVR) size at baseline and through 52 weeks post-transplant. To measure the reservoir accurately, they utilized the advanced intact proviral DNA assay. Consequently, they compared the LVR levels between participants who experienced rejection and those who did not.
The results were quite revealing for the transplant community. Surprisingly, the researchers found no significant differences in the size of the latent reservoir between the two groups. This lack of difference held true regardless of the donor's HIV status. Therefore, the presence or size of the latent virus does not seem to be the primary driver of acute rejection episodes in this population.
These findings provide essential evidence supporting the feasibility of organ transplantation between HIV-positive individuals. Furthermore, the study suggests that the increased rejection risk in PLWH likely stems from other factors. These factors may include complex interactions with immunosuppressive medications or specific T-cell responses. Physicians can now feel more confident in the safety profiles of donor-positive transplants regarding viral reservoir dynamics.
Clinicians should continue to monitor kidney transplant recipients with HIV closely for rejection. However, they can take reassurance from the fact that the latent reservoir size does not appear to correlate with rejection risk. As we expand the use of the HOPE Act protocols, these biological insights remain vital for optimizing patient management and long-term graft survival.
No, recent research indicates there is no significant difference in the latent HIV reservoir size between patients who experience rejection and those who do not.
Yes, data from the latest studies support the feasibility and safety of HIV+ to HIV+ organ transplantation, showing no negative impact related to the viral reservoir.
The study used the intact proviral DNA assay to evaluate the reservoir size at baseline and up to one year after the transplant procedure.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Sulaiman A et al. Allograft Rejection and the Latent HIV Reservoir in Kidney Transplant Recipients with HIV. J Infect Dis. 2026 Mar 13. doi: undefined. PMID: 41823991.
2. Glicklich D, Nog R. HIV in kidney transplantation. Curr Opin Organ Transplant. 2022 Feb 1;27(1):65-71.
3. Durand CM et al. Safety of Kidney Transplantation from Donors with HIV. N Engl J Med. 2024 Oct 17;391(15):1390-1401.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New research finds no link between latent HIV reservoir size and kidney transplant rejection, supporting the feasibility of HIV+ to HIV+ organ donation....
5 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today